J. Apperley

S. Brett, K. Rezvani, D. Marin, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

D. Marin, J. Goldman, M. Bua, 2005, Cancer.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

D. Strunk, A. Nagler, F. Sánchez-Guijo, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

E. Lam, D. Marin, F. Villanova, 2010, Haematologica.

Running title: MSC-mediated protection of CML cells from imatinib

D. Marin, F. Villanova, A. Gomes, 2009 .

State-of-the-art in the treatment of chronic myeloid leukaemia

D. Milojković, J. Apperley, D. Milojković, 2008, Current opinion in oncology.

Platelet function in patients with chronic myeloid leukemia treated with asciminib

M. Laffan, D. Milojković, J. Apperley, 2020, Leukemia & lymphoma.

leukemia after allogeneic stem cell transplantation Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid

C. Craddock, D. Marin, J. Goldman, 2013 .

chronic myeloid leukemia Factors affecting duration of survival after onset of blastic transformation of

D. Marin, J. Goldman, A. Chase, 2013 .

Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia.

J. Apperley, P. Garland, 2011, Future oncology.

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib

J. Melo, D. Marin, J. Goldman, 2009, Haematologica.

Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.

J. Melo, F. Mahon, J. Apperley, 2005, Blood.

Personalized medical treatment strategies for patients with chronic myeloid leukemia

D. Marin, J. Apperley, C. Burton, 2005, Expert review of anticancer therapy.

Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients (*)

J. Melo, J. Goldman, J. Apperley, 2005 .

Stem cell transplantation for chronic myeloid leukemia in children.

S. Iacobelli, R. Brand, G. Dini, 2003, Blood.

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.

C. Craddock, D. Marin, J. Goldman, 2002, Blood.

ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.

I. Lampert, J. Goldman, A. Chase, 2002, American journal of clinical pathology.

The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.

D. Marin, J. Goldman, M. Bua, 2002, Haematologica.

Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse

C. Craddock, J. Goldman, N. Cross, 2001, British journal of haematology.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

K. Rezvani, D. Marin, J. Goldman, 2008, Blood.

The argument for using imatinib in CML.

J. Apperley, S. Claudiani, 2018, Hematology. American Society of Hematology. Education Program.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

CML and tyrosine kinase inhibition: the hope becomes reality.

J. Apperley, 2015, The Lancet. Haematology.

Managing pregnancy in chronic myeloid leukaemia

D. Milojković, J. Apperley, R. Palani, 2015, Annals of Hematology.

2 prior lines of TKI therapy failed patients with chronic myeloid leukemia in chronic phase who have Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in

K. Rezvani, J. Goldman, L. Foroni, 2013 .

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

D. Marin, T. Holyoake, J. Goldman, 2010, Haematologica.

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

D. Marin, J. Goldman, D. Milojković, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

R. Brand, C. Crawley, A. Gratwohl, 2006, Haematologica.

allogeneic HSCT in first chronic phase allogeneic HSCT not in first chronic phase autologous HSCT in first chronic phase autologous HSCT not in first chronic phase

C. Crawley, H. Kolb, T. Ruutu, 2006 .

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

D. Marin, J. Goldman, M. Bua, 2005, Leukemia.

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.

D. Marin, J. Goldman, M. Bua, 2003, Haematologica.

Chronic myeloid leukemia.

J. Melo, T. Hughes, J. Apperley, 2003, Hematology. American Society of Hematology. Education Program.

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy

D. Marin, J. Goldman, M. Bua, 2007, Leukemia.

Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons

D. Marin, J. Goldman, S. Marley, 2003, British journal of haematology.

The post‐transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase

D. Blaise, R. Clark, G. Meloni, 2002, British journal of haematology.

Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia

N. Schmitz, W. Siegert, G. Gahrton, 1996, British journal of haematology.

Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

M. Sorror, J. Wingard, M. Gilleece, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma

P. Croucher, M. Greaves, R. Russell, 1999 .

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Y. Natkunam, R. Siebert, D. de Jong, 2022, Leukemia.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

R. Gale, L. Foroni, G. Gerrard, 2019, Haematologica.

HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML)

J. Falkenburg, R. Willemze, A. Gratwohl, 2000, Leukemia.

HLA-B 8 and HLA-A 3 Coexpressed With HLA-B 8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia

J. Falkenburg, R. Willemze, A. Gratwohl, 1999 .

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.

J. Falkenburg, R. Willemze, A. Gratwohl, 1999, Blood.

Late effects of transplantation

H. Kolb, G. Socié, J. Apperley, 1999, The Lancet.

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT

D. Slade, D. Marin, J. Goldman, 2013, Bone Marrow Transplantation.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia

R. Clark, D. Marin, J. Goldman, 2013, British journal of haematology.

Umbilical cord blood progenitor cell transplantation. The International Conference Workshop on Cord Blood Transplantation, Indianapolis, November 1993.

J. Apperley, 1994, Bone marrow transplantation.

LATE‐ONSET HEMORRHAGIC CYSTITIS ASSOCIATED WITH URINARY EXCRETION OF POLYOMA VIRUSES AFTER BONE MARROW TRANSPLANTATION

J. Goldman, T. Krausz, S. Gardner, 1987, Transplantation.

Primary plasma cell leukemia and autologous stem cell transplantation

S. Iacobelli, G. Gahrton, D. Niederwieser, 2010, Haematologica.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

M. Caligiuri, R. Garzon, J. Goldman, 2013, Blood.

Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity.

J. Apperley, K. Ward, H. Ang, 1997, Blood.

Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma

J. Goldman, E. Terpos, A. Rahemtulla, 2003, British journal of haematology.

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.

D. Marin, J. Goldman, L. Foroni, 2012, Blood.

photopheresis for treatment of chronic graft-versus-host disease A multicenter prospective phase 2 randomized study of extracorporeal

L. Bouzas, A. Elmaagacli, R. Knobler, 2013 .

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.

L. Bouzas, D. Parenti, A. Elmaagacli, 2008, Blood.

Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease

R. Başar, K. Rezvani, D. Marin, 2018, Front. Immunol..

Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab.

J. Sanz, J. Apperley, J. Perz, 2007, Transplant immunology.

Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis

C. Craddock, J. Goldman, F. Dazzi, 2001, British journal of haematology.

Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia.

Apperley, L. J., J. Goldman, 1986, Blood.

Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

N. Kröger, M. Mohty, F. Lanza, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma

M. Bua, H. Auner, A. Rahemtulla, 2011, Bone Marrow Transplantation.

No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.

E. Terpos, I. Kotsianidis, A. Karadimitris, 2006, Leukemia research.

Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma

I. Lampert, K. Naresh, E. Terpos, 2005, Acta Haematologica.

non-permissive mismatches for hematological stem cell transplantation A T cell epitope encoded by a subset of HLA-DPB1 alleles determines

M. Sormani, M. Martinetti, E. Lanino, 2013 .

AT-cell epitope encoded by a subset of HLA-DPB 1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation

M. Sormani, G. Ferrara, M. Martinetti, 2004 .

positive chronic eosinophilic leukemia - FIP1L1-PDGFRA responses and achievement of complete molecular remission in Low-dose imatinib mesylate leads to rapid induction of major molecular

M. Rondoni, G. Martinelli, C. Preudhomme, 2013 .

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.

S. Iacobelli, G. Gahrton, C. Crawley, 2007, Blood.

after allogeneic stem cell transplantation Direct visualization of cytomegalovirus-specific T-cell reconstitution

C. Craddock, P. Moss, J. Ainsworth, 2012 .

HLA‐A3 increases and HLA‐DR1 decreases the risk of acute graft‐versus‐host disease after HLA‐matched sibling bone marrow transplantation for chronic myelogenous leukaemia

R. Clark, A. Gratwohl, D. Niederwieser, 2001, British journal of haematology.

Immune neutropenia associated with anti‐human neutrophil antigen‐2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony‐stimulating factor

J. Goldman, K. Rezvani, J. Apperley, 2001, British Journal of Haematology.

Biochemical bone markers in patients with multiple myeloma.

J. Apperley, S. Girgis, D. Samson, 1996, Clinica chimica acta; international journal of clinical chemistry.

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis

D. Marin, J. Goldman, D. Milojković, 2008, British journal of haematology.

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome

M. Labopin, A. Gratwohl, D. Niederwieser, 1998, Bone Marrow Transplantation.

Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS

M. Labopin, G. Meloni, A. Gratwohl, 1997 .

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

N. Kröger, S. Iacobelli, I. Yakoub-Agha, 2021, Clinical lymphoma, myeloma & leukemia.

Efficacy and outcome of autologous transplantation in rare myelomas

H. Goldschmidt, G. Morgan, S. Iacobelli, 2009, Haematologica.

T‐cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement

S. Stewart, S. Whittaker, J. Apperley, 2001, British journal of haematology.

High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.

C. Craddock, M. Seckl, G. Rustin, 1998, British Journal of Cancer.

Dual inhibition of ras and bcr‐abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission

D. Marin, C. Chuah, J. Goldman, 2007, British journal of haematology.

Differences between graft product and donor side effects following bone marrow or stem cell donation

N. Schmitz, M. Beksac, A. Nagler, 2003, Bone Marrow Transplantation.

Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.

M. Baccarani, J. Dipersio, H. Kantarjian, 2014 .

Allogeneic Transplantation for CML

J. Radich, C. Crawley, J. Apperley, 2007 .

Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation.

J. Apperley, 2006, Hematology. American Society of Hematology. Education Program.

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

J. Sierra, A. Zander, A. Nagler, 2005, Blood.

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation

M. Horowitz, D. Parenti, F. Foss, 2010, Bone Marrow Transplantation.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.

G. Rosti, J. Cortes, M. Deininger, 2021, Blood.

Hematology: Imatinib—should we have more of a good thing?

J. Apperley, 2010, Nature Reviews Clinical Oncology.

Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation

A. Gratwohl, A. Bosi, V. Leblond, 1998 .

Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation.

M. Labopin, G. Meloni, A. Gratwohl, 1997, Blood.

TWIST it but don't spin it.

J. Apperley, 2013, Blood.

Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia

J. Apperley, J. Pavlů, 2013, Current Hematologic Malignancy Reports.

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

D. Marin, J. Goldman, P. Mehta, 2008, Blood.

11 Bone marrow transplant for the haemoglobinopathies: past, present and future

J. Apperley, 1993 .

Bone marrow transplant for the haemoglobinopathies: past, present and future.

J. Apperley, 1993, Bailliere's clinical haematology.

Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms.

J. Melo, E. Robinet, P. Tiberghien, 2002, Blood.

Bisphosphonates in multiple myeloma.

P. Croucher, J. Apperley, 1999, Pathologie-biologie.

Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.

H. Einsele, M. Labopin, D. Niederwieser, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cloning of a novel membrane-linked metalloproteinase from human myeloma cells.

P. Croucher, R. Russell, J. Apperley, 1996, The Biochemical journal.

Proposal for a novel prognostic index ( RANKL ) / osteoprotegerin ( OPG ) ratio predicts survival in multiple

J. Goldman, E. Hatjiharissi, E. Terpos, 2003 .

BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.

E. Lam, J. Melo, C. Rivas, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection

D. Milojković, J. Apperley, L. Cook, 2020, British journal of haematology.

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2014 .

LACE‐conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B‐cell lymphoma: treatment outcome and risk factor analysis from a single centre

K. Naresh, H. Auner, A. Rahemtulla, 2011, Hematological oncology.

Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients

R. Marcus, N. Russell, A. Newland, 1994, British journal of haematology.

Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.

C. Craddock, J. Goldman, A. Chase, 2000, Haematologica.

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

C. Craddock, J. Goldman, N. Cross, 2000 .

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia

C. Craddock, J. Goldman, A. Chase, 2000 .

Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.

R. Marcus, H. Waldmann, J. Apperley, 1986, Bone marrow transplantation.

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

R. Clark, L. Bonnett, J. Apperley, 2021, Cancers.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

J. Byrne, M. Copland, R. Clark, 2019, The Lancet. Haematology.

Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study

J. Byrne, M. Copland, R. Clark, 2019 .

High-dose melphalan and stem cell rescue for AL amyloidosis

C. Craddock, M. Pepys, J. Apperley, 1999 .

Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis

R. Marcus, D. Catovsky, J. Goldman, 1989, British journal of haematology.

Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).

G. Martinelli, A. Gollerkeri, A. Hochhaus, 2006 .

Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.

M. Baccarani, H. Kantarjian, B. Druker, 2006 .

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

J. Cortes, A. Gollerkeri, R. Silver, 2006 .

Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.

R. Marcus, P. Mahendra, J. Apperley, 1995, Leukemia & lymphoma.

Experimental models for peripheral blood stem cell autografting

C. Craddock, M. Gordon, J. Apperley, 1992 .

Mesenchymal stromal stem cell (MSC) immunotherapy for experimental septic shock: systematic review and meta-analysis with trial sequential analysis of mortality

K. Harrington, S. Brett, M. Laffan, 2016 .

Successful use of liposome encapsulated amphotericin to treat invasive aspergillosis following failure of conventional amphotericin.

J. Apperley, R. E. Marcus, E. M. Richards, 2008, Clinical and laboratory haematology.

Identical twin marrow transplantation for 5 patients with chronic myeloid leukaemia: Role of DNA finger‐printing to confirm monozygosity in 3 cases

A. Jeffreys, D. Catovsky, J. Goldman, 1987, European journal of haematology.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

R. Aguiar, N. Cross, P. Rousselot, 2014, Blood.

Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH‐296

J. Melo, J. Goldman, A. Miller, 1999, British journal of haematology.

Severe events in donors after allogeneic hematopoietic stem cell donation

N. Schmitz, A. Gratwohl, H. Baldomero, 2009, Haematologica.

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.

N. Schmitz, M. Beksac, A. Nagler, 2005, Haematologica.

Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

M. Hickson, D. Milojković, A. Chaidos, 2019, Clinical nutrition.

The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study

C. Fegan, J. Byrne, J. Snowden, 2006, British journal of haematology.

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

D. Marin, J. Goldman, D. Milojković, 2007, Blood.

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.

L. Foroni, G. Gerrard, M. Alikian, 2016, Leukemia research.

Duplex quantitative PCR for molecular monitoring of BCR‐ABL1‐associated hematological malignancies

D. Marin, J. Goldman, L. Foroni, 2011, American journal of hematology.

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

M. Labopin, A. Gratwohl, D. Niederwieser, 1998, Bone marrow transplantation.

Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation

A. Gratwohl, D. Niederwieser, J. Hermans, 2001, Leukemia.

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.

J. Radich, J. Apperley, E. Olavarría, 2004, Hematology/oncology clinics of North America.

transplantation for chronic myeloid leukemia polymerase chain reaction predicts outcome after allogeneic stem cell - Early detection of BCR-ABL transcripts by quantitative reverse transcriptase

C. Craddock, K. Rezvani, N. Cross, 2013 .

Myelodysplastic Syndromes or Leukemia Following MDS Treated with Allogeneic Bone Marrow Transplantation: A Survey of the Working Party on Chronic Leukemia of the European Cooperative Group for Blood and Marrow Transplantation

A. Gratwohl, D. Niederwieser, J. Hermans, 1997 .

Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.

S. Mackinnon, D. Catovsky, J. Goldman, 1990, Experimental hematology.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2018, Biology of Blood and Marrow Transplantation.

The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products

A. Gratwohl, H. Baldomero, K. Frauendorfer, 2008, Bone Marrow Transplantation.

The EBMT activity survey 2008: impact of team size, team density and new trends

A. Gratwohl, H. Baldomero, A. Schwendener, 2011, Bone Marrow Transplantation.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2017, Haematologica.

High‐dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single‐centre experience

C. Craddock, J. Goldman, J. Apperley, 2000, British journal of haematology.

Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality

D. Milojković, P. May, D. Bansal, 2019, Leukemia.

Assessment of quantitative polymerase chain reaction for BCR–ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?

L. Foroni, G. Gerrard, D. Milojković, 2022, British journal of haematology.

Providing molecular diagnosis and monitoring of patients with chronic myeloid leukemia in Abuja, Nigeria

E. I. David, J. Apperley, O. Ogbe, 2017 .

Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).

J. Cortes, Jianxiang Wang, H. Khoury, 2010 .

Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.

M. Baccarani, H. Kantarjian, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

M. Baccarani, H. Kantarjian, J. Cortes, 2008 .

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia

L. Foroni, D. Milojković, J. Apperley, 2020, British journal of haematology.

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors

G. Saglio, J. Janssen, A. Hochhaus, 2020, Leukemia.

The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients

D. Milojković, J. Apperley, J. Khorashad, 2019, Leukemia & lymphoma.

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

L. Foroni, D. Milojković, J. Apperley, 2019, Haematologica.

The EBMT: History, Present, and Future

M. Mohty, A. Gratwohl, J. Apperley, 2018, The EBMT Handbook.

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Martin C. Müller, I. Dufva, G. Martinelli, 2011, Blood.

accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase

J. Radich, R. Larson, M. Gobbi, 2008 .

Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia

J. Radich, R. Larson, M. Gobbi, 2008 .

Part II: management of resistance to imatinib in chronic myeloid leukaemia.

J. Apperley, 2007, The Lancet. Oncology.

Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines

J. Apperley, Pratap Neelakantan, 2013 .

Chronic myeloid leukemia-transplantation in the tyrosine kinase era.

J. Apperley, A. Innes, 2014, Hematology/oncology clinics of North America.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013 .

CML in pregnancy and childhood.

J. Apperley, 2009, Best practice & research. Clinical haematology.

Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

K. Rezvani, D. Marin, J. Goldman, 2009, British journal of haematology.

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

J. Cortes, F. Guilhot, N. Shah, 2005 .

“Stem cell transplantation: its importance today”

J. Apperley, J. Pavlů, J. Chakrabartty, 2012, memo - Magazine of European Medical Oncology.

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Factors for graft‐versus‐host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose

J. Goldman, F. Dazzi, C. Fozza, 2007, British journal of haematology.

Autologous Peripheral Blood Stem Cell Transplantation in Tumor‐stage Mycosis Fungoides: Predictors of Disease‐free Survival

S. Whittaker, J. Apperley, F. Child, 2001, Annals of the New York Academy of Sciences.

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

M. Baccarani, H. Kantarjian, F. Haluska, 2016 .

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

D. Milojković, J. Apperley, J. Khorashad, 2020, Haematologica.

BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation

D. Marin, J. Goldman, L. Foroni, 2012, American journal of hematology.

karyopherin inhibitor KPT-330 in Ph Preclinical and clinical efficacy of XPO 1 / CRM 1 inhibition by the

M. Caligiuri, R. Garzon, J. Goldman, 2013 .

Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.

D. Marin, J. Goldman, D. Milojković, 2007, Blood.

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

J. Dipersio, G. Rosti, J. Cortes, 2022, American journal of hematology.

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis

I. Dufva, G. Martinelli, J. Cortes, 2008 .

need for further investigation into the effects of discontinuing imatinib therapy in those patients who wish to conceive.

K. Rezvani, D. Marin, J. Goldman, 2017 .

The impact of dasatinib on pregnancy outcomes

J. Cortes, M. Guha, J. Apperley, 2015, American journal of hematology.

without having achieved an optimal response myeloid leukemia who interrupt therapy on account of pregnancy Poor outcome after reintroduction of imatinib in patients with chronic

K. Rezvani, D. Marin, J. Goldman, 2013 .

Issues of imatinib and pregnancy outcome.

J. Apperley, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

Brief report EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

D. Marin, J. Goldman, L. Foroni, 2010 .

Anti-tumour activity of bisphosphonates in human myeloma cells.

P. Croucher, M. Rogers, R. Graham, 1998, Leukemia & lymphoma.

Combined Inhibition of p 97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

Philippa, N. Dillon, T. Ward, 2019 .

Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

N. Dillon, T. Ward, A. Chaidos, 2013, PLoS ONE.

Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation

A. Ganser, N. Kröger, H. Sengeløv, 2013, Haematologica.

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.

R. Brand, A. Gratwohl, D. Niederwieser, 2002, Blood.

Pharmacokinetics of CAMPATH-1H in BMT patients.

M. Varughese, J. Apperley, K. Cwynarski, 2001, Cytotherapy.

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.

D. Marin, J. Goldman, N. Cross, 2006, Blood.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

M. Kattan, N. Kröger, A. Nagler, 2014, Bone Marrow Transplantation.

The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells.

E. Matutes, M. Gordon, J. Apperley, 1989, Experimental hematology.

Brief report Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

K. Rezvani, D. Marin, J. Goldman, 2011 .

Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party

H. Einsele, A. Gratwohl, D. Niederwieser, 2007, Leukemia.

Long-term physiological side effects after allogeneic bone marrow transplantation.

M. Mohty, J. Apperley, 2010, Hematology. American Society of Hematology. Education Program.

Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis

C. Mathias, A. Rahemtulla, J. Apperley, 2006, Bone Marrow Transplantation.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation

S. Beck, M. Widschwendter, V. Rakyan, 2015, Genome Medicine.

achieve durable long-term remissions with imatinib fusion genes PDGFRB Patients with myeloid malignancies bearing

R. Aguiar, P. Rousselot, C. Dunbar, 2014 .

The FIP1L1-PDGFRA syndrome: a case of mistaken identity?

B. Bain, J. Apperley, 2004 .

Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)

A. Gratwohl, D. Niederwieser, J. Hermans, 2002, British journal of haematology.

Group for Blood and Marrow Transplantation Marrow Transplantation: A Prospective Cohort Study of the European Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or

A. Gratwohl, A. Bosi, V. Leblond, 2013 .

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

H. Einsele, A. Zander, G. Gahrton, 2005, Blood.

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres

G. Gahrton, N. Russell, R. Willemze, 2001, British journal of haematology.

Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.

J. Melo, P. Tiberghien, C. Ferrand, 2001, Blood.

Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF

W. Wiktor-Jedrzejczak, M. Mohty, F. Lanza, 2012, Bone Marrow Transplantation.

Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation

Clare L. Bennett, F. Watt, T. S. Cheung, 2017, Science Translational Medicine.

Transplantation study from the European Group for Blood and Marrow transplantation in multiple myeloma: a retrospective case-matched Allogeneic bone marrow transplantation versus autologous stem cell

R. Marcus, J. Hermans, H. Prentice, 2011 .

Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose.

C. Craddock, J. Goldman, K. Rezvani, 2001, The hematology journal : the official journal of the European Haematology Association.

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

C. Craddock, J. Goldman, N. Cross, 2000, Blood.

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides

R. Jones, S. Whittaker, A. Chaidos, 2007, Bone Marrow Transplantation.

Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation

G. Gahrton, A. Gratwohl, J. Reiffers, 1999, Bone Marrow Transplantation.

Chronic myeloid leukemia in first chronic phase not responding to α-interferon: outcome and prognostic factors after autologous transplantation

G. Meloni, J. Reiffers, C. Carlo-Stella, 1999, Bone Marrow Transplantation.

ADULT RESPIRATORY DISTRESS SYNDROME AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION: EVIDENCE FOR A NEUTROPHIL-INDEPENDENT MECHANISM

J. Goldman, T. Krausz, J. Apperley, 1985, The Lancet.

The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).

M. Labopin, A. Gratwohl, J. Hermans, 1996, Leukemia & lymphoma.

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

J. Byrne, M. Copland, R. Clark, 2017, The Lancet. Haematology.

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies

D. Milojković, A. Chaidos, M. Bua, 2022, Nature Communications.

Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib‐responsive myeloproliferative neoplasms

A. Chase, F. Grand, N. Cross, 2010, British journal of haematology.

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

J. Melo, J. Goldman, J. Apperley, 2006, Blood.

Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics.

K. Naresh, D. Marin, A. Reid, 2009, Leukemia research.

Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party

M. Labopin, A. Nagler, M. Mohty, 2020, Bone Marrow Transplantation.

Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial.

H. Einsele, M. Labopin, D. Niederwieser, 2010, Vaccine.

Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.

D. Marin, J. Goldman, J. Apperley, 2006, Blood.

Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene.

A. Hagenbeek, P. Tiberghien, C. Ferrand, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Treatment of CML in pregnancy.

J. Apperley, Harry F. Robertson, Harry F Robertson, 2022, Hematology. American Society of Hematology. Education Program.

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations

M. Mauro, J. Apperley, E. Abruzzese, 2020, Therapeutic advances in hematology.

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

D. Marin, J. Goldman, L. Foroni, 2011 .

Just Another Cost Increasing Exercise (JACIE)?

J. Apperley, 2004, Bone Marrow Transplantation.

Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment.

J. Goldman, J. Apperley, E. Olavarría, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With Chronic Myelogenous Leukemia

P. Bartolomeo, G. Gahrton, J. Hermans, 2000 .

EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.

K. Rezvani, D. Marin, J. Goldman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety of retroviral gene marking with a truncated NGF receptor

A. Hagenbeek, E. Weissinger, J. Falkenburg, 2003, Nature Medicine.

Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation

A. Tichelli, H. Prentice, P. Ljungman, 1999, Annals of Internal Medicine.

Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia.

T. Sutedja, J. Goldman, P. Nunn, 1988, Thorax.

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

D. Marin, L. Foroni, A. Reid, 2012, Haematologica.

Efficacy of combining dasatinib and intensive chemotherapy for patients with chronic myeloid leukemia in blastic transformation

D. Marin, L. Foroni, A. Reid, 2011 .

Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells.

David A. Williams, S. Orkin, B. Lim, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Escalating-Dose HLA-mismatched donor lymphocyte infusion is safe for the treatment of 1 leukaemia relapse following alemtuzumab-based myeloablative allogeneic stem cell 2 transplantation.

D. Slade, K. Rezvani, J. Goldman, 2013 .

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

D. Marin, A. Reid, J. Apperley, 2008, Molecular Cytogenetics.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measurable residual disease in chronic myeloid leukemia

J. Apperley, S. Branford, 2022, Haematologica.

Subacute thyroiditis after bone marrow transplant for chronic granulocytic leukaemia.

J. Goldman, J. Apperley, J. Ball, 1987, Bone marrow transplantation.

Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides

M. Laffan, F. Dazzi, J. Apperley, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

C. Schiffer, R. Larson, M. Baccarani, 2020, Leukemia.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

PHYSICIAN PERCEPTIONS AND PRACTICE PATTERNS REGARDING FERTILITY PRESERVATION IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

M. Sorror, J. Wingard, J. Pidala, 2013, Bone Marrow Transplantation.

Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.

F. Aversa, A. Nardi, H. Prentice, 1993, Blood.

The effects of imatinib on pregnancy outcome.

G. Rosti, J. Cortes, J. Apperley, 2008, Blood.

Defining the intensity of conditioning regimens: working definitions.

B. Sandmaier, D. Blaise, M. Pasquini, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?

R. Gale, J. Apperley, 2019, Current Hematologic Malignancy Reports.

Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation

J. Gribben, G. Janossy, J. Goldman, 1986, British journal of haematology.

Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.

R. Fanin, M. Baccarani, J. Apperley, 1999, Haematologica.

FOSCARNET FOR CYTOMEGALOVIRUS PNEUMONITIS

J. Apperley, J. M. Goldman, D. Wardle, 1985, The Lancet.

How I treat leukemia during pregnancy.

J. Apperley, D. Milojković, D. Milojkovic, 2014, Blood.

The European LeukemiaNet: achievements and perspectives

P. Schrotz-King, H. Döhner, H. Einsele, 2011, Haematologica.

JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation.

I. Slaper-Cortenbach, J. Apperley, D. Pamphilon, 2009, Hematology/oncology and stem cell therapy.

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

J. Goldman, J. Apperley, Richard Szydlo, 2011, Blood.

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

N. Kröger, P. Ljungman, S. Mielke, 2021, Leukemia.

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program

A. Gratwohl, D. Niederwieser, F. Lanza, 2012, Bone Marrow Transplantation.

JACIE celebrates its 10-year anniversary with the demonstration of improved clinical outcome.

A. Gratwohl, D. Niederwieser, F. Lanza, 2011, Cytotherapy.

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

W. Wiktor-Jedrzejczak, N. Kröger, J. Finke, 2014, Bone Marrow Transplantation.

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.

C. Craddock, P. Moss, J. Ainsworth, 2001, Blood.

A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation

C. Craddock, J. Goldman, J. Apperley, 1999, Bone Marrow Transplantation.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide

P. Chiusolo, R. Brand, G. Martinelli, 2014, Transfusion.

Cytomegalovirus: biology, clinical features and methods for diagnosis.

J. Apperley, J. M. Goldman, J. Goldman, 1988, Bone marrow transplantation.

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

J. Goldman, E. Hatjiharissi, E. Terpos, 2003, Blood.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

B. Bain, J. Melo, D. Marin, 2002, The New England journal of medicine.

Regulation of advanced therapy medicinal products in Europe and the role of academia.

E. Mischak-Weissinger, H. Greinix, A. Dickinson, 2013, Cytotherapy.

Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma

J. Melo, C. Rivas, E. Simpson, 2000, Cancer Gene Therapy.

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity

P. Croucher, M. Rogers, R. Russell, 1997, British journal of haematology.

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

D. Marin, J. Goldman, I. Roberts, 2012, Blood.

Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect

W. Gregory, F. Mandelli, G. Papa, 1988, British journal of haematology.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

M. Baccarani, J. Cortes, A. Gollerkeri, 2007, Blood.

Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression.

D. Williams, J. Apperley, B. Luskey, 1991, Blood.

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

A. Ganser, P. Bruzzi, A. Santoro, 2009, The Lancet. Oncology.

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

C. Craddock, J. Goldman, J. Apperley, 2000, Leukemia.

Bone marrow transplantation for patients with chronic myeloid leukemia.

R. Marcus, D. Catovsky, J. Goldman, 1986, The New England journal of medicine.

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines

Richard T. Lee, G. Daley, R. Barker, 2016, Stem cell reports.

A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation.

Maria Pia Sormani, Franco Locatelli, Daniela Lisini, 2003, Blood.

Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.

A. Miller, J. Apperley, J. M. Goldman, 2000, Virology.

Cost and quality issues in establishing hematopoietic cell transplant program in developing countries.

M. Aljurf, M. Pasquini, H. Greinix, 2017, Hematology/oncology and stem cell therapy.

Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.

J. Kurtzberg, M. Labopin, K. Leung, 2017, Blood.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation

D. Marin, A. Chaidos, H. Auner, 2013, Leukemia & lymphoma.

Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes.

J. Glowacki, S. Mizuno, J. Arbiser, 1994, The Journal of clinical investigation.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

K. Rezvani, D. Marin, E. Shpall, 2013, Blood.

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

J. Melo, N. Cross, M. Sobrinho-Simões, 2010, Blood.

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.

C. Craddock, K. Piper, S. Siddique, 2007, Blood.

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.

R. Garzon, B. Calabretta, M. Deininger, 2020, Blood cancer discovery.

The Role of Hematopoietic Stem Cell Transplantation in CML

A. Gratwohl, J. Apperley, 2021, Hematologic Malignancies.

Intermediate‐dose busulphan before autografting for advanced‐phase chronic myeloid leukaemia

J. Goldman, J. Reilly, S. O’Brien, 1996, British journal of haematology.

Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system

K. Rezvani, D. Marin, J. Goldman, 2012, British journal of haematology.

Chronic myeloid leukemia: reminiscences and dreams

G. Daley, J. Radich, J. Cortes, 2016, Haematologica.

chronic-phase chronic myeloid leukemia after failure of imatinib therapy Dasatinib induces notable hematologic and cytogenetic responses in

Martin C. Müller, M. Baccarani, H. Kantarjian, 2013 .

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

J. Apperley, D. Milojković, D. Milojkovic, 2009, Clinical Cancer Research.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

M. Baccarani, H. Kantarjian, B. Druker, 2007, Blood.

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.

D. Marin, J. Goldman, M. Bua, 2003, Haematologica.

Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report

Avik Datta, I. Barozzi, P. Piazza, 2020, Frontiers in Oncology.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

D. Marin, J. Goldman, L. Foroni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression

E. Nacheva, J. Apperley, C. Grace, 2007, Genes, chromosomes & cancer.

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

J. Melo, M. Mohty, J. Apperley, 2007, Blood.

The polycomb group BMI 1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia

Junia V. Melo, Jane F. Apperley, J. Melo, 2007 .

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

D. Marin, J. Goldman, A. Chase, 2002, Blood.

The Current Status of Bone Marrow Transplantation and Gene Therapy in the Management of the Haemoglobinopathies

I. Roberts, J. Apperley, 1995 .

Gene Transfer into Murine Hematopoietic Stem Cells and Bone Marrow Stromal Cells

David A. Williams, S. Orkin, B. Lim, 1990, Annals of the New York Academy of Sciences.

GENE THERAPY: CURRENT STATUS AND FUTURE DIRECTIONS

J. Apperley, David A. Williams, 1990, British journal of haematology.

Williams long-term expression hematopoietic cells : effect of selectable marker sequences on Retroviral gene transfer of human adenosine deaminase in murine

D. Williams, J. Apperley, B. Luskey, 2003 .

Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles

S Mackinnon, N H Russell, J A Madrigal, 2010, Leukemia.

Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.

S. Iacobelli, R. Brand, A. Gratwohl, 2002, Blood.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

M. Rondoni, G. Martinelli, C. Preudhomme, 2007, Blood.

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

J. Goldman, A. Chase, F. Dazzi, 1998, Bone Marrow Transplantation.

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.

C. Craddock, J. Goldman, N. Cross, 2001, Blood.

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

J. Apperley, 2007, The Lancet. Oncology.

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

H. Kantarjian, G. Martinelli, J. Cortes, 2017, Cancer.

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

L. Staudt, A. Rosenwald, T. Greiner, 2012, Blood.

Chronic myeloid leukaemia

J. Apperley, 2015, The Lancet.

Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation

A. Tichelli, P. Ljungman, G. Socié, 1997, Annals of Internal Medicine.

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

J. Melo, D. Marin, S. Kamel‐Reid, 2006 .

Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience

G. Gahrton, G. Juliusson, S. Mackinnon, 2000 .

Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia

A. Little, S. Marsh, J. Apperley, 1999, British journal of haematology.

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis

K. Naresh, M. Deininger, K. Ponnusamy, 2021, Cancers.

Complete remission after autografting for chronic myeloid leukaemia.

J. Goldman, F. Rassool, J. Apperley, 1987, Leukemia research.

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

J Hermans, A. Gratwohl, D. Niederwieser, 2000, Blood.

ANTIBODY TITRES TO A ROUGH-MUTANT STRAIN OF ESCHERICHIA COLI IN PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION Evidence of a Protective Effect Against Graft-versus-host Disease

J. Apperley, V. Aber, R. Moore, 1987, The Lancet.

Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow.

D. Catovsky, J. Goldman, J. Apperley, 1987, Clinical and experimental immunology.

Stem cell transplantation and high-dose chemotherapy

Deena Iskander, J. Apperley, J. Pavlů, 2013 .

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

L. Foroni, S. Hing, J. Apperley, 2015 .

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

J. Gribben, L. Bullinger, P. Sonneveld, 2022, ESMO Open.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

J. Radich, R. Larson, M. Gobbi, 2008, Blood.

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

R. Clark, D. Marin, J. Goldman, 2012, Blood.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

S. Jagannath, G. Gahrton, D. Reece, 1998, British journal of haematology.

Hotspots during Leukemic Transformation of B Cell Precursors Graphical

L. Castellano, J. Stebbing, P. May, 2017 .

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation

R. Brand, A. Nagler, J. Snowden, 2017, Leukemia.

Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity Authors

Tom R. Gaunt, Christa, Federica, 2016 .

Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions.

J. Goldman, F. Dazzi, J. Apperley, 2002, Blood.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

T. Clackson, M. Baccarani, J. Dipersio, 2013, The New England journal of medicine.

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

R. Larson, M. Baccarani, J. Lipton, 2007, Blood.

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

N. Schmitz, D. Hasenclever, A. Nagler, 2002, Blood.

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Jaspal Kaeda, D. Marin, J. Goldman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical decisions for chronic myeloid leukemia in the imatinib era.

D. Marin, J. Goldman, J. Apperley, 2003, Seminars in hematology.

Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions

C. Craddock, J. Goldman, F. Dazzi, 2001, Bone Marrow Transplantation.

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

B. Druker, L. Jave-Suárez, A. Reid, 2021, Oncogene.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

M. Caligiuri, J. Byrd, C. Croce, 2013, The Journal of clinical investigation.

A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia

A. Mead, J. Byrne, M. Copland, 2020, British journal of haematology.

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.

Jim F Huggett, Alexandra S Whale, Simon Cowen, 2016, Clinical chemistry.

intention-to-treat analysis in chronic myeloid leukemia patients Responses to second-line tyrosine kinase inhibitors are durable: an

K. Rezvani, D. Marin, J. Goldman, 2013 .

Fast‐mode duplex qPCR for BCR‐ABL1 molecular monitoring: Innovation, automation, and harmonization

N. Cross, H. White, L. Foroni, 2012, American journal of hematology.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

K. Rezvani, R. Clark, D. Marin, 2012, Blood.

Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase.

J. Goldman, F. Rassool, J. Apperley, 1988, Blood.

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.

A. Gratwohl, A. Bosi, V. Leblond, 1998, Blood.

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients

I. Lampert, K. Naresh, E. Terpos, 2006, Bone Marrow Transplantation.

Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology

A. Gratwohl, H. Baldomero, A. Schwendener, 2010, Haematologica.

Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors

N. Russell, S. Mackinnon, J. Madrigal, 2016, Haematologica.

J. Apperley, E. Olavarría, S. Altaf, 2016, Seminars in hematology.

Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.

J. Apperley, J. Perz, Richard Szydlo, 2005 .

Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States.

A. Nagler, J. Szer, D. Niederwieser, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Increased frequencies of CD4+CD25high Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

R. Lechler, F. Dazzi, J. Apperley, 2007, Leukemia.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

S. Mustjoki, B. Druker, J. Cortes, 2019, Leukemia.

HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome

A. Barrett, S. Mackinnon, J. Goldman, 1992, British journal of haematology.

Risk score for outcome after allogeneic hematopoietic stem cell transplantation

R. Brand, G. Dini, A. Gratwohl, 2009, Cancer.

Outcome of Second Allogeneic Transplants Using Reduced Intensity Conditioning Following Relapse after an Initial Allogeneic Transplant.

G. Mufti, C. Craddock, N. Russell, 2006 .

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

W. Wiktor-Jedrzejczak, N. Kröger, J. Finke, 2014, Bone Marrow Transplantation.

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.

C. Craddock, J. Goldman, A. Chase, 2000, Blood.

Philadelphia‐positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia

J. Goldman, F. Rassool, C. Harrison, 1986, American journal of hematology.

The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants

N. Kröger, S. Iacobelli, A. Zander, 2005, Bone Marrow Transplantation.

siblings with standard-risk leukemia Transplantation of mobilized peripheral blood cells to HLA-identical

D. Hasenclever, A. Nagler, N. Russell, 2013 .

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

N. Kröger, M. Mohty, F. Lanza, 2012, Bone Marrow Transplantation.

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond.

P. Hari, P. Watry, J. Snowden, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation.

D. Marin, G. Williams, J. Apperley, 2007, Leukemia research.

Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005

C. Craddock, J. Madrigal, J. Goldman, 2006, Bone Marrow Transplantation.

Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

R. Brand, A. Gratwohl, H. Baldomero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced incidence of GVHD in recipients of t-cell depleted marrow

J. Goldman, H. Waldmann, J. Apperley, 1986 .

Analysis of Rejection in HLA Matched T-Depleted Bone Marrow Transplants

J. Gribben, G. Janossy, J. Goldman, 1985 .

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

J. Melo, G. McArthur, J. Goldman, 2007, Blood.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

R. Clark, R. Gale, L. Foroni, 2017, Haematologica.

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).

J. Byrne, M. Copland, R. Clark, 2019, Blood.

Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation.

A. Gratwohl, J. Hermans, A. Bosi, 1995, Blood.

Haematopoietic stem cell transplantation for vasculitis including Behçet’s disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature

A. Gratwohl, E. Jantunen, A. Attarbaschi, 2006, Annals of the rheumatic diseases.

A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease

B. Gazzard, A. Chaidos, M. Nelson, 2008, AIDS.

Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined significance (MGUS)

M. Dimopoulos, E. Terpos, M. Laffan, 2004, British journal of haematology.

Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents

A. Ganser, V. Meineke, B. Sirohi, 2006, Annals of Hematology.

Radiation Emergencies: Evaluation, Management, and Transplantation

J. Wingard, D. Weisdorf, N. Chao, 2007 .

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

A. Chambery, G. Acton, A. Leonardi, 2019, Toxicology reports.

Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy

A. Reid, C. Mason, J. Apperley, 2020, British journal of haematology.

Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

T. Stijnen, N. Kröger, R. Brand, 2015, EBioMedicine.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

R M Stone, R. Larson, H. Dombret, 2008, Leukemia.

Autologous Infusion of Expanded Mobilized Adult Bone Marrow-Derived CD34+ Cells Into Patients With Alcoholic Liver Cirrhosis

Shahid A. Khan, N. Habib, M. Scott, 2008, The American Journal of Gastroenterology.

Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrowand mobilised peripheral blood

J. Melo, J. Apperley, M. Garin, 2000, European journal of haematology.

Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting.

M. Lishner, M. Fumagalli, F. Amant, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors

H. Goldschmidt, J. Apperley, D. Samson, 1997, British journal of haematology.

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Heikki Joensuu, Richard Herrmann, J. Fletcher, 2008, Clinical Cancer Research.

literature Rheumatism databases and a review of the Transplantation and European League Against recorded in the European Bone Marrow polychondritis: a retrospective analysis of patients vasculitis including Behçet's disease and Haematopoietic stem cell transplantation for

A. Gratwohl, E. Jantunen, P. Guardiola, 2007 .

Engraftment of T‐cell‐depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen

C. Craddock, J. Goldman, S. Kreiter, 2000, British journal of haematology.

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.

J. Melo, M. Mohty, J. Goldman, 2008, Blood.

Long‐term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease

N. Habib, S. Marley, M. Gordon, 2007, Cell proliferation.

Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia.

K. Sikora, S. Mackinnon, J. Goldman, 1989, Clinical radiology.

Predictability of hematopoietic stem cell transplantation rates

A. Gratwohl, H. Baldomero, A. Schwendener, 2007, Haematologica.

Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey.

A. Gratwohl, H. Baldomero, B. Labar, 2004, Croatian medical journal.

Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative

C. Craddock, E. Tholouli, C. Crawley, 2020, Bone Marrow Transplantation.

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

S. Montoto, S. Iacobelli, J. Sierra, 2022, Journal of clinical medicine.

Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions.

J. Goldman, F. Dazzi, J. Apperley, 2004, Experimental hematology.

Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.

D. Marin, J. Apperley, J. Perz, 2006, Haematologica.

HIV infection due to a platelet transfusion after allogeneic bone marrow transplantation

J. Goldman, J. Barbara, J. Apperley, 1987, European journal of haematology.

Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma

H. Goldschmidt, A. Benner, K. Thielemans, 2004, British journal of haematology.

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, M. Robin, 2014, Haematologica.

Haematopoietic stem cell transplantation

J. Apperley, Marrow Transplantation, 2008 .

Chimerism induction and delayed onset of cytomegalovirus (CMV) infection after allogeneic reduced-intensity stem cell transplantation (RIST)

J. Apperley, Richard Szydlo, 2002 .

Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission.

J P Klein, J. Klein, C. Craddock, 2000, Blood.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation

S. Beck, M. Widschwendter, V. Rakyan, 2015, Genome Medicine.

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase

R. Clark, D. Marin, L. Foroni, 2015, American journal of hematology.

Herpes Simplex Virus Thymidine Kinase-Transduced Human T Lymphocytes

A. Hagenbeek, C. Ferrand, J. Apperley, 2003 .

Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same

R. Gale, J. Apperley, 2015, Bone Marrow Transplantation.

Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT

S. Iacobelli, I. Yakoub-Agha, D. Blaise, 2021, European journal of haematology.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation

M. Labopin, I. Yakoub-Agha, A. Nagler, 2018, American journal of hematology.

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond.

P. Hari, P. Watry, J. Snowden, 2020, Hematology/oncology and stem cell therapy.

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma.

P. Croucher, M. Greaves, R. Russell, 1999, British journal of haematology.

Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival

E. Tholouli, J. Snowden, A. Vora, 2019, British journal of haematology.

Mesenchymal stromal cells for the treatment of steroid-resistant acute graft versus host disease: factors influencing clinical responses.

E. Tholouli, J. Snowden, A. Vora, 2017 .

Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia

W. Siegert, R. Brand, H. Bickeböller, 2010, Haematologica.

Autologous/syngeneic stem cell transplantation to treat refractory GvHD

J. Mehta, A. Gratwohl, J. Goldman, 2004, Bone Marrow Transplantation.

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

L. Bouzas, A. Elmaagacli, H. Greinix, 2006 .

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

M. Robin, I. Yakoub-Agha, J. Byrne, 2022, American journal of hematology.

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).

M. Baccarani, H. Kantarjian, J. Cortes, 2017 .

Survival after bone-marrow transplantation

C. Craddock, M. Cobbold, J. Goldman, 2002, The Lancet.

A. Gratwohl, N. Gorin, J. Apperley, 2000 .

The platelet-derived growth factor receptor beta fuses to two distinct loci at 3p21 in imatinib responsive chronic eosinophilic leukemia

F. Grand, N. Cross, J. Gotlib, 2005 .

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia

H. Putter, R. Brand, A. Nagler, 2019, EClinicalMedicine.

adiation Emergencies : Evaluation , Management , nd Transplantation

J. Wingard, N. Chao, N. Gorin, 2007 .

Donor lymphocyte infusions (dli) for cml: Factors influencing the effective cell dose and implications for the definition of refractoriness

J. Goldman, M. Gilleece, F. Dazzi, 2000 .

BKV‐specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA‐haploidentical haematopoietic cell transplantation

O. Pello, J. Apperley, E. Olavarría, 2017, European journal of haematology.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous trasnplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma

Christof, W. Wiktor-Jedrzejczak, N. Kröger, 2022 .

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

N. Schmitz, N. Kröger, S. Iacobelli, 2016, Annals of Hematology.

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

R. Larson, M. Baccarani, G. Martinelli, 2014 .

Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias.

G. Meloni, J. Reiffers, C. Carlo-Stella, 1999, Bone marrow transplantation.

Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT.

G. Meloni, J. Reiffers, J. Apperley, 1994, Bone marrow transplantation.

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.

M. Copland, R. Clark, J. Apperley, 2021, Blood advances.

European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization

M. Mohty, F. Lanza, G. Basak, 2012, Transfusion.

33: Increased CD4+CD25high+ regulatory T-cell are associated with disease relapse after allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia (CML)

R. Lechler, F. Dazzi, J. Apperley, 2007 .

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

J. Goldman, A. Rahemtulla, J. Apperley, 2004, Leukemia.

Successful pregnancy after allogeneic bone marrow transplantation for chronic myeloid leukaemia

J. Goldman, J. Apperley, R. Winston, 1994, The Lancet.

Uptake and outcome of assisted reproductive techniques in long-term survivors of SCT

J. Goldman, J. Apperley, N. Salooja, 2012, Bone Marrow Transplantation.

Never say never again

J. Apperley, 2006 .

Because Htlv-i–transformed Cells Are

Macchi, J. Apperley, Hammersmith Hospital, 2022 .

Zodiac as a Predictor of Survival for Recipients of an llogeneic Stem Cell Transplant for Chronic Myeloid Leukaemia CML ) : An Artificial Association

J. Apperley, E. Olavarría, M. Szydło, 2022 .

Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling

R. Muschel, Danmei Xu, J. Apperley, 2018, Blood Cancer Journal.

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

J. Dipersio, H. Kantarjian, G. Rosti, 2020 .

Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma

A. Chambery, G. Acton, A. Leonardi, 2018, British journal of haematology.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Katayoun Rezvani, Holger W Auner, K. Rezvani, 2010, Blood.

Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.

J. Goldman, H. Auner, J. Apperley, 2009 .

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

J. Wason, B. Ramsahoye, J. Byrne, 2018, Blood.

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

G. Rosti, J. Cortes, F. Guilhot, 2007 .

The 14q32.31 DLK1-DIO3 MIR300 tumor suppressor promotes leukemogenesis by inducing cancer stem cell quiescence and inhibiting NK cell anti-cancer immunity

R. Garzon, B. Calabretta, M. Deininger, 2019, bioRxiv.

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

S. Kapoor, M. Mauro, A. Hochhaus, 2023, Leukemia.

Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

R. Larson, H. Kantarjian, J. Cortes, 2008 .

Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.

M. Baccarani, H. Kantarjian, F. Haluska, 2014 .

Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

H. Kantarjian, G. Martinelli, J. Cortes, 2015 .

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Martin C. Müller, R. Larson, M. Baccarani, 2016, Journal of the National Cancer Institute.

Plastic-adherent progenitor cells in mobilized peripheral blood progenitor cell collections.

R. Marcus, M. Gordon, J. Apperley, 1995, Blood.

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

J. Cortes, M. Deininger, G. Verhoef, 2020 .

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

J. Byrne, M. Copland, R. Clark, 2014 .

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

D. Marin, J. Goldman, L. Foroni, 2009 .

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

S. Kapoor, J. Cortes, M. Mauro, 2021, Blood.

Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival

D. Marin, J. Goldman, L. Foroni, 2008 .

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

G. Rosti, J. Cortes, M. Deininger, 2020 .

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

J. Byrne, R. Clark, D. Marin, 2011, Haematologica.

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

R. Clark, D. Marin, J. Goldman, 2011 .

CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial.

G. Rosti, J. Cortes, M. Deininger, 2022, Clinical lymphoma, myeloma & leukemia.

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

G. Rosti, M. Deininger, C. Chuah, 2021 .

Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia

M. Mauro, J. Apperley, M. Trawinska, 2018, European journal of haematology.

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

J. Dipersio, H. Kantarjian, G. Rosti, 2021, Blood.

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

D. Marin, J. Goldman, L. Foroni, 2012 .

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

D. Barraco, Dong-Wook Kim, F. Nicolini, 2022, Blood.

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Dong-Wook Kim, J. Apperley, E. Abruzzese, 2018, Blood.

Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis

M. Mauro, Dong-Wook Kim, J. Apperley, 2018, Blood.

The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations

D. Marin, J. Goldman, M. Bua, 2007 .

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

D. Marin, A. Reid, J. Apperley, 2008, Cancer genetics and cytogenetics.

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

R. Yeh, M. Baccarani, G. Martinelli, 2009, Leukemia.

Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation

J. Marchesi, F. Davies, E. Brannigan, 2021, Frontiers in Cellular and Infection Microbiology.

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

J. Byrne, M. Copland, R. Clark, 2015 .

Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myeloma

K. Rezvani, S. Basu, E. Terpos, 2005, European Journal of Haematology.

Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality

E. Brannigan, B. Mullish, J. Apperley, 2017, Bone Marrow Transplantation.

COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

D. Altmann, R. Boyton, C. Pade, 2022, Leukemia.

C‐reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early‐ and long‐term mortality

A. Chaidos, H. Auner, A. Karadimitris, 2018, British journal of haematology.

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

T. Clackson, H. Kantarjian, J. Cortes, 2017 .

BK VIRUS AS CAUSE OF HAEMORRHAGIC CYSTITIS AFTER BONE MARROW TRANSPLANTATION

S. Gardner, J. Apperley, S. Rice, 1985, The Lancet.

Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation

H. Goldschmidt, H. Katus, F. Sack, 2006, Clinical Research in Cardiology.

Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study

R. Tedder, J. Apperley, Myra O. McClure, 2022, Leukemia & lymphoma.

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Martin C. Müller, M. Baccarani, H. Kantarjian, 2015 .

The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland

C. Craddock, N. Russell, J. Apperley, 2004, British Journal of Haematology.

C. Craddock, N. Russell, J. Byrne, 2011, British journal of haematology.

Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group.

C. Craddock, J. Byrne, R. Clark, 2002 .

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia

J. Byrne, M. Copland, J. Apperley, 2023, Bone Marrow Transplantation.

Erratum: Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice (Bone Marrow Transplantatio (2014) 49 (319) DOI:10.1038/bmt.2013.210)

W. Wiktor-Jedrzejczak, N. Kröger, J. Finke, 2014 .

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

K. Rezvani, D. Marin, J. Goldman, 2011 .

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

Martin C. Müller, M. Baccarani, J. Dipersio, 2012 .

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13)

B. Bain, J. Apperley, A. Hastings, 2020, American journal of hematology.

Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

G. Rosti, J. Cortes, M. Deininger, 2022, Blood.

An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets

J. Apperley, S. Loaiza, Avirup Chowdhury, 2020, British journal of haematology.

The European Group for Blood and Marrow Transplantation (EBMT): a report from the president and the chairmen of the working parties.

A. Fischer, A. Gratwohl, P. Ljungman, 1996, Bone marrow transplantation.

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

D. Kasperavičiūtė, J. Huggett, Michael Mueller, 2016, The Journal of molecular diagnostics : JMD.

for chronic myeloid leukemia patients on long-term therapy Poor adherence is the main reason for loss of CCyR and imatinib failure

K. Rezvani, D. Marin, L. Foroni, 2013 .

Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia (CML): an artificial association.

J. Apperley, E. Olavarría, I. Gabriel, 2010, Transplantation proceedings.

The importance of patient selection in nonmyeloablative stem cell transplant (NMSCT) for acute and chronic leukaemia, myelodysplastic syndrome, and myeloma

G. Gahrton, S. Mackinnon, F. Frassoni, 2000 .

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

M. Baccarani, H. Kantarjian, B. Druker, 2007 .

Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With Chronic Myelogenous Leukemia

A. Bosi, M. Boogaerts, A. Bacigalupo, 2017 .

Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling

Xing Fu, R. Muschel, Danmei Xu, 2018, Blood Cancer Journal.

Responses to second-line tyrosine kinase inhibitors are durable : an intention-to-treat analysis in chronic myeloid leukemia patients

K. Rezvani, D. Marin, J. Goldman, 2012 .

Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy

S. Brett, A. Rahemtulla, J. Apperley, 2014, Leukemia & lymphoma.

Bone Marrow Transplantation for Patients in the Chronic Phase of Chronic Granulocytic Leukaemia: Apparent Low Incidence of Relapse within the First Two Years Post-BMT

R. Marcus, D. Catovsky, J. Goldman, 1985 .

How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib

J. Melo, N. Cross, J. Score, 2007 .

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

K. Rezvani, D. Marin, J. Goldman, 2012, Blood.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Martin C. Müller, I. Dufva, G. Martinelli, 2010 .

Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

A. Gratwohl, J. Hermans, J. Apperley, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

How I treat leukemia during pregnancy.

J. Apperley, D. Milojkovic, 2014, Blood.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

J. Apperley, 2007, The Lancet. Oncology.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

M. Baccarani, H. Kantarjian, B. Druker, 2007, Blood.

PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation

M. Baccarani, J. Dipersio, H. Kantarjian, 2013 .

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy

D. Marin, J. Goldman, M. Laffan, 2012, Haematologica.

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines

G. Daley, N. Benvenisty, S. Piantadosi, 2016, Stem cell reports.

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

R. Clark, D. Marin, J. Goldman, 2011 .

Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions.

J. Goldman, F. Dazzi, J. Apperley, 2002, Blood.

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

G. Rosti, M. Deininger, C. Chuah, 2022, Blood.

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

J. Goldman, E. Hatjiharissi, E. Terpos, 2003, Blood.

Fast‐mode duplex qPCR for BCR‐ABL1 molecular monitoring: Innovation, automation, and harmonization

N. Cross, H. White, L. Foroni, 2012, American journal of hematology.

Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States.

A. Nagler, J. Szer, D. Niederwieser, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

K. Rezvani, D. Marin, J. Goldman, 2011, Haematologica.

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Long-term physiological side effects after allogeneic bone marrow transplantation.

M. Mohty, J. Apperley, 2010, Hematology. American Society of Hematology. Education Program.